US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022
Executive Summary
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.
You may also be interested in...
PDUFA Fees Push Higher In FY 2024, While Biosimilar Fees Race Downward
Fiscal year 2024 prescription drug user fees skyrocket in part because of a low application volume in FY 2022, while biosimilar user fees continue to drop due to the program’s healthy operating reserve.
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.